Cyclerion Therapeutics Price To Sales vs. Return On Asset
| CYCN Stock | USD 2.57 0.04 1.58% |
Cyclerion Therapeutics Price To Sales Ratio |
|
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.9 | 0.7811 |
|
|
For Cyclerion Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Cyclerion Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Cyclerion Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Cyclerion Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Cyclerion Therapeutics over time as well as its relative position and ranking within its peers.
Cyclerion |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclerion Therapeutics. If investors know Cyclerion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclerion Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.29) | Revenue Per Share 0.586 | Quarterly Revenue Growth 0.141 | Return On Assets (0.47) | Return On Equity (1.50) |
The market value of Cyclerion Therapeutics is measured differently than its book value, which is the value of Cyclerion that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclerion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclerion Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclerion Therapeutics' market value can be influenced by many factors that don't directly affect Cyclerion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclerion Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclerion Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclerion Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cyclerion Therapeutics Return On Asset vs. Price To Sales Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Cyclerion Therapeutics's current stock value. Our valuation model uses many indicators to compare Cyclerion Therapeutics value to that of its competitors to determine the firm's financial worth. Cyclerion Therapeutics is rated third in price to sales category among its peers. It also is rated third in return on asset category among its peers . At this time, Cyclerion Therapeutics' Price To Sales Ratio is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cyclerion Therapeutics' earnings, one of the primary drivers of an investment's value.Cyclerion Return On Asset vs. Price To Sales
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Cyclerion Therapeutics |
| = | 55.50 X |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Cyclerion Therapeutics |
| = | -0.47 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Cyclerion Return On Asset Comparison
Cyclerion Therapeutics is currently under evaluation in return on asset category among its peers.
Cyclerion Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Cyclerion Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Cyclerion Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Cyclerion Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Cyclerion Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -12 K | -12.6 K | |
| Operating Income | -9.6 M | -10.1 M | |
| Net Loss | -41.1 M | -43.1 M | |
| Income Before Tax | -12.6 M | -13.2 M | |
| Total Other Income Expense Net | -2.9 M | -2.8 M | |
| Net Loss | -50.7 M | -53.2 M | |
| Net Loss | -5.3 M | -5.5 M | |
| Income Tax Expense | 8.4 M | 8.8 M | |
| Net Interest Income | 389 K | 525.4 K | |
| Interest Income | 358 K | 653.8 K | |
| Non Operating Income Net Other | 529.2 K | 1 M | |
| Change To Netincome | 7.2 M | 13.2 M | |
| Net Loss | (8.99) | (9.44) | |
| Income Quality | 4.04 | 4.24 | |
| Net Income Per E B T | 1.67 | 0.90 |
Cyclerion Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Cyclerion Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Cyclerion Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Cyclerion Therapeutics' important profitability drivers and their relationship over time.
Use Cyclerion Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cyclerion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclerion Therapeutics will appreciate offsetting losses from the drop in the long position's value.Cyclerion Therapeutics Pair Trading
Cyclerion Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Cyclerion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cyclerion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cyclerion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cyclerion Therapeutics to buy it.
The correlation of Cyclerion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cyclerion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cyclerion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cyclerion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Cyclerion Therapeutics position
In addition to having Cyclerion Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Cash Cows Thematic Idea Now
Cash Cows
Entities with stable and reliable earnings or profits, which allows them to pay consistent dividends to their shareholders. The Cash Cows theme has 25 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cash Cows Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. To learn how to invest in Cyclerion Stock, please use our How to Invest in Cyclerion Therapeutics guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
To fully project Cyclerion Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Cyclerion Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Cyclerion Therapeutics' income statement, its balance sheet, and the statement of cash flows.